Follow The Filings

NEOG Neogen Corporation

Health Care, filed as NEOGEN CORP (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 Owner
  • Max 0.1%
  • $45M
  • 1 add

In 2026 Q2 Ron Baron added to Neogen.

Who owns this now

Largest portfolio weights among holders, up to 0.1% (Ron Baron, Bamco Inc. (Baron Capital)). Not free-float ownership.

  1. Ron Baron Add 0.07%

Who owns NEOG

Sorted by value, long equity only, as of 2026 Q2.

History
Ron Baron, Bamco Inc. (Baron Capital) 0.07% Add +0.1% 5,015,968 $45M History

1 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by NEOG's executives, directors and 10% owners in the last 12 months, from their Form 4s

All NEOG insider trades
  • $14K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Mikheal Nassif CEO
    Buy
    $6,035 505 shares at $11.95 +47% to stake
    Traded Oct 9 Filed Oct 9
    ↗
  2. Mikheal Nassif CEO
    Buy
    $4,370 370 shares at $11.81 +53% to stake
    Traded Aug 4 Filed Aug 6
    ↗
  3. Mikheal Nassif CEO
    Buy
    $252 23 shares at $10.94 +3.4% to stake
    Traded Feb 17 Filed Feb 17
    ↗
  4. Mikheal Nassif CEO
    Buy
    $486 49 shares at $9.93 +7.8% to stake
    Traded Jan 26–Feb 2 Filed Feb 2
    ↗
  5. Mikheal Nassif CEO
    Buy
    $1,279 137 shares at $9.33 +28% to stake
    Traded Jan 16 Filed Jan 16
    ↗
  6. Mikheal Nassif CEO
    Buy
    $1,106 177 shares at $6.25 +56% to stake
    Traded Nov 3, 2025 Filed Nov 7, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 26 stock grants, 18 option exercises, and 11 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
10-Q Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
DEFA14A Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02 Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 43 minutes ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025 FY2026
Revenue $822.45M $924.22M $894.66M $870.4M
Gross profit $405.96M $463.9M $421.38M $408.5M
Gross margin * 49.4% 50.2% 47.1% 46.9%
Net income -$0.023B -$0.009B -$1.09B -$0.008B
Net margin * -2.8% -1.0% -122.1% -0.9%

Balance sheet

Metric FY2023 FY2024 FY2025 FY2026
Total current assets $585.93M $589.23M $576.94M $604.6M
Total non-current assets * $3.97B $3.96B $2.87B $2.74B
Total assets $4.55B $4.55B $3.44B $3.35B
Total current liabilities $145.47M $154.32M $174.01M $158.2M
Total non-current liabilities * $1.27B $1.25B $1.2B $1.09B
Total equity $3.13B $3.14B $2.07B $2.09B

Cash flow

Metric FY2023 FY2024 FY2025 FY2026
Cash from operations $41.03M $35.26M $58.24M $83.2M
Cash from investing $201.04M -$29.31M -$99.2M $70.5M
Cash from financing -$118.08M $1.92M -$1.6M -$99.4M
Net change in cash $118.77M $7.37M -$41.61M $56.5M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.